Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03 - Escherich, G; Zimmermann, M; Janka-Schaub, G (Pediatric blood & cancer, 2013)
et al.